Jerini's focus is on the discovery, development, and commercialization of drugs both independently and with partners. Currently, Jerini offers the following partnering opportunities:

• α5β1 Integrin receptor antagonist for oncology
• C5a receptor antagonists for renal therapy

Contact:
Dr. Rainer Kramer
Vice President Business Development

Jerini AG
Invalidenstrasse 130
10115 Berlin
Germany
T +49-30-978 93-506
F +49-30-978 93-599